Important Updates to Diabetes Medical Care Standards – 2022 Incorporate New Evidence

PR Newswire

ARLINGTON, Virginia, May 31, 2022

ARLINGTON, Va., May 31, 2022 /PRNewswire/ — Today, the American Diabetes Association® (ADA) has released important updates on the Standards of Medical Care for Diabetes—2022 (Standards of Care)in annotations like Care living standards. The changes include new data on:

Important Updates to Diabetes Medical Care Standards — 2022 Incorporate New Evidence

  • Finerenone and its effects in people with type 2 diabetes and chronic kidney disease on cardiovascular outcomes

  • SGLT2 inhibitors and their effects in people with type 2 diabetes on heart failure and kidney outcomes

  • New information on the calculation of eGFR and the inclusion of race for the diagnosis of kidney disease

These changes were prompted by recently published research and were developed and approved by the ADA’s Professional Practice Committee, which is responsible for developing the Standards of care. Updates to Section 10, Cardiovascular Diseases and Risk Management, have also been reviewed and approved by the American College of Cardiology, which endorses this section. The Care living standards are immediately available online at Diabetic treatments®.

Updates to Care living standards include information added to the following sections:

  • Section 10 has been updated to include evidence of Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved), the Dapagliflozin in the PRESERVED Ejection Fraction Heart Failure Trial (PRESERVED-HF)the Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Renal Impairment (FIDELIO-DKD)and the Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease Diagnostic Clinical Trial (FIGARO-DKD).

  • Section 11 has been amended to include proof of Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) trial, the Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Renal Impairment (FIDELIO-DKD) trial, and the Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Clinical Diagnosis of Diabetic Renal Failure (FIGARO-DKD) as well as the recommendations of the NKF-ASN working group on the reassessment of the inclusion of race in the diagnosis of kidney disease.

“This is the fifth year that we have been able to update the Standards of care after its publication on our Care living standards updates, helping to provide diabetes care providers with the most important information and latest evidence relevant to their practice,” said Dr. Robert Gabby, scientific and medical director of the ADA. “With an estimated 537 million adults living with diabetes worldwide, it’s important to provide providers with the latest research through our guidelines as we learn more.”

The Standards of care provides the latest comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2, or gestational diabetes; strategies to improve the prevention or delay of type 2 diabetes; and therapeutic approaches that reduce complications and have a positive effect on health outcomes. In 2018, the ADA began updating and revising the online version of the Standards of care throughout the year with annotations for new evidence or regulatory changes that merit immediate incorporation. The online version of Standards of care now includes any research updates or policy changes approved throughout 2022.

The complete, annotated Standards of carewhich includes updates made today, is available online at Diabetic treatments. The Abbreviated Standards of Medical Care for Diabetes has also been updated and can be viewed online at clinical diabetes®.

About Diabetic treatments
Diabetic treatments, a monthly journal of the ADA, is the highest-ranked peer-reviewed journal in the field of diabetes treatment and prevention. Dedicated to increasing knowledge, stimulating research and promoting better health care for people with diabetes, the journal publishes original articles on human studies in clinical care, education and nutrition ; epidemiology, health services and psychosocial research; emerging treatments and technologies; and pathophysiology and complications. Diabetic treatments also publishes ADA recommendations and statements, clinically relevant review articles, editorials, and commentaries. Topics covered are of interest to physicians, researchers, epidemiologists, psychologists, diabetes care and education specialists, and other healthcare professionals.

About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve of the diabetes epidemic and help people with diabetes thrive. For 81 years, the ADA has driven discovery and research to treat, manage and prevent diabetes while working tirelessly for a cure. Through advocacy, program development and education, we aim to improve the quality of life for the more than 133 million Americans with diabetes or prediabetes. Diabetes brought us together. What we do next will make us connected for life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

Contact: Daisy Diaz, 703-253-4807
[email protected]

(PRNewsFoto/American Diabetes Association)

(PRNewsFoto/American Diabetes Association)

Quote

Quote

View original content to download multimedia: https://www.prnewswire.com/news-releases/important-updates-to-the-standards-of-medical-care-in-diabetes2022-incorporate-new-evidence-301558105 .html

SOURCE American Diabetes Association